Cullinan Therapeutics outlines fourth-quarter 2026 data plans across three T cell engager programsSep 24Clinical readoutCLN-049CLN-978
Cullinan reports Q2 2026 results, outlines T cell engager trial timelinesAug 6Quarterly updateCullinan Therapeutics Inc.
Cullinan Therapeutics registers Phase 1b trial of CLN-049 with azacitidine, venetoclax in AMLJul 23Trial updateazacitidineCLN-049
Sign inSign in